Excess Protein O-GlcNAcylation Links Metabolic Derangements to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

The hexosamine biosynthetic pathway (HBP) converts glucose to uridine-diphosphate-N-acetylglucosamine, which, when added to serines or threonines, modulates protein function through protein O-GlcNAcylation. Glutamine-fructose-6-phosphate amidotransferase (GFAT) regulates HBP flux, and AMP-kinase phosphorylation of GFAT blunts GFAT activity and O-GlcNAcylation. While numerous studies demonstrate increased right ventricle (RV) glucose uptake in pulmonary arterial hypertension (PAH), the relationship between O-GlcNAcylation and RV function in PAH is unexplored. Therefore, we examined how colchicine-mediated AMP-kinase activation altered HBP intermediates, O-GlcNAcylation, mitochondrial function, and RV function in pulmonary artery-banded (PAB) and monocrotaline (MCT) rats. AMPK activation induced GFAT phosphorylation and reduced HBP intermediates and O-GlcNAcylation in MCT but not PAB rats. Reduced O-GlcNAcylation partially restored the RV metabolic signature and improved RV function in MCT rats. Proteomics revealed elevated expression of O-GlcNAcylated mitochondrial proteins in MCT RVs, which fractionation studies corroborated. Seahorse micropolarimetry analysis of H9c2 cardiomyocytes demonstrated colchicine improved mitochondrial function and reduced O-GlcNAcylation. Presence of diabetes in PAH, a condition of excess O-GlcNAcylation, reduced RV contractility when compared to nondiabetics. Furthermore, there was an inverse relationship between RV contractility and HgbA1C. Finally, RV biopsy specimens from PAH patients displayed increased O-GlcNAcylation. Thus, excess O-GlcNAcylation may contribute to metabolic derangements and RV dysfunction in PAH.

[1]  S. Egginton,et al.  Energy Metabolism in the Failing Right Ventricle: Limitations of Oxygen Delivery and the Creatine Kinase System , 2019, International journal of molecular sciences.

[2]  Jianguo Xia,et al.  MetaboAnalystR 2.0: From Raw Spectra to Biological Insights , 2019, Metabolites.

[3]  S. Archer,et al.  Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease , 2019, Journal of the American Heart Association.

[4]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[5]  S. Archer,et al.  Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again , 2018, Journal of the American Heart Association.

[6]  X. Prieur,et al.  Chronic O-GlcNAcylation and Diabetic Cardiomyopathy: The Bitterness of Glucose , 2018, Front. Endocrinol..

[7]  Charles T. Hindmarch,et al.  Transcriptomic Signature of Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension: Deep Sequencing Demonstrates Mitochondrial, Fibrotic, Inflammatory and Angiogenic Abnormalities , 2018, International journal of molecular sciences.

[8]  I. Douglas,et al.  Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement , 2018, American journal of respiratory and critical care medicine.

[9]  C. Y. Chen,et al.  Microtubules provide a viscoelastic resistance to myocyte motion , 2018, bioRxiv.

[10]  K. Margulies,et al.  Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure , 2018, Nature Medicine.

[11]  Ami A. Shah,et al.  Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis–Associated Versus Idiopathic Pulmonary Arterial Hypertension , 2018, Circulation.

[12]  G. Hansmann,et al.  PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation , 2018, Science Translational Medicine.

[13]  B. Viollet,et al.  AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation , 2018, Nature Communications.

[14]  R. Swerdlow,et al.  Sustained O-GlcNAcylation reprograms mitochondrial function to regulate energy metabolism , 2017, The Journal of Biological Chemistry.

[15]  S. Archer,et al.  Colchicine Depolymerizes Microtubules, Increases Junctophilin‐2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension , 2017, Journal of the American Heart Association.

[16]  D. Stewart,et al.  Shifts in myocardial fatty acid and glucose metabolism in pulmonary arterial hypertension: a potential mechanism for a maladaptive right ventricular response. , 2016, European heart journal cardiovascular Imaging.

[17]  S. Archer,et al.  Pulmonary Pulse Wave Transit Time is Associated with Right Ventricular–Pulmonary Artery Coupling in Pulmonary Arterial Hypertension , 2016, Pulmonary circulation.

[18]  Ami A. Shah,et al.  Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension , 2016, Circulation.

[19]  Junfeng Ma,et al.  Comparative Proteomics Reveals Dysregulated Mitochondrial O-GlcNAcylation in Diabetic Hearts. , 2016, Journal of proteome research.

[20]  T. Griffin,et al.  Slx5/Slx8 Promotes Replication Stress Tolerance by Facilitating Mitotic Progression. , 2016, Cell reports.

[21]  H. Ahmadzadeh,et al.  Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes , 2016, Science.

[22]  Huiliang Zhang,et al.  Microtubule-Mediated Misregulation of Junctophilin-2 Underlies T-Tubule Disruptions and Calcium Mishandling in mdx Mice , 2016, JACC. Basic to translational science.

[23]  R. Gerszten,et al.  Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension , 2016, Circulation.

[24]  G. Wright,et al.  Diabetes is an independent predictor of right ventricular dysfunction post ST-elevation myocardial infarction , 2016, Cardiovascular Diabetology.

[25]  Junfeng Ma,et al.  O-GlcNAcomic Profiling Identifies Widespread O-Linked β-N-Acetylglucosamine Modification (O-GlcNAcylation) in Oxidative Phosphorylation System Regulating Cardiac Mitochondrial Function*♦ , 2015, The Journal of Biological Chemistry.

[26]  M. Pillinger,et al.  Colchicine: old and new. , 2015, The American journal of medicine.

[27]  Junfeng Ma,et al.  Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria , 2015, Proceedings of the National Academy of Sciences.

[28]  R. Dweik,et al.  O -Linked β - N -Acetylglucosamine Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension , 2015 .

[29]  Katsuya Suzuki,et al.  Cardiotoxic Changes of Colchicine Intoxication in Rats: Electrocardiographic, Histopathological and Blood Chemical Analysis , 2014, Journal of toxicologic pathology.

[30]  S. Archer,et al.  The Right Ventricle in Pulmonary Arterial Hypertension: Disorders of Metabolism, Angiogenesis and Adrenergic Signaling in Right Ventricular Failure , 2014, Circulation research.

[31]  E. Brittain,et al.  Impact of Diabetes on Survival and Right Ventricular Compensation in Pulmonary Arterial Hypertension , 2014, Pulmonary circulation.

[32]  W. Fang,et al.  The Ratio of 18F-FDG Activity Uptake Between the Right and Left Ventricle in Patients With Pulmonary Hypertension Correlates With the Right Ventricular Function , 2014, Clinical nuclear medicine.

[33]  E. Michelakis,et al.  The metabolic basis of pulmonary arterial hypertension. , 2014, Cell metabolism.

[34]  J. Shabanowitz,et al.  Cross-talk between Two Essential Nutrient-sensitive Enzymes , 2014, The Journal of Biological Chemistry.

[35]  D. Baltimore,et al.  Activation of the Transcriptional Function of the NF-κB Protein c-Rel by O-GlcNAc Glycosylation , 2013, Science Signaling.

[36]  J. Ryan,et al.  Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension , 2013, Journal of Molecular Medicine.

[37]  P. Fawcett,et al.  Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. , 2013, Physiological genomics.

[38]  S. Archer,et al.  Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension , 2013, Pulmonary circulation.

[39]  W. Fang,et al.  Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease , 2012, Pulmonary circulation.

[40]  S. Archer,et al.  Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[41]  I. Haber,et al.  Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[42]  Steven P Jones,et al.  O-GlcNAc Signaling in the Cardiovascular System , 2010, Circulation research.

[43]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[44]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[45]  Sanjiv J. Shah,et al.  Contemporary Survival in Patients with Pulmonary Arterial Hypertension: A Reappraisal of the National Institutes of Health Risk Stratification Equation , 2009 .

[46]  Jing Chen,et al.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..

[47]  U. Kikkawa,et al.  AMP‐activated protein kinase phosphorylates glutamine : fructose‐6‐phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity , 2009, Genes to cells : devoted to molecular & cellular mechanisms.

[48]  S. Trauger,et al.  Increased Enzymatic O-GlcNAcylation of Mitochondrial Proteins Impairs Mitochondrial Function in Cardiac Myocytes Exposed to High Glucose* , 2009, Journal of Biological Chemistry.

[49]  B. Spiegelman,et al.  AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α , 2007, Proceedings of the National Academy of Sciences.

[50]  J. E. Kudlow,et al.  Induction of Macrophage Glutamine: Fructose-6-Phosphate Amidotransferase Expression by Hypoxia and by Picolinic Acid , 2007, International journal of immunopathology and pharmacology.

[51]  B. Spiegelman,et al.  AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Richard Mateosian,et al.  Old and New , 2006, IEEE Micro.

[53]  M. Mann,et al.  Modular stop and go extraction tips with stacked disks for parallel and multidimensional Peptide fractionation in proteomics. , 2006, Journal of proteome research.

[54]  Kuo-Chen Chou,et al.  Molecular therapeutic target for type-2 diabetes. , 2004, Journal of proteome research.